Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...

NULISA employs a sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to ...